TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces that it has extended the term of a consulting agreement, as amended, previously announced June 11, 2025 and November 21, 2025, with a third party branding expert to provide strate
Technology, Healthcare and Hospitals, Health
2025-12-31 6:00 PM EST | FendX Technologies Inc.
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-31 5:00 PM EST | TempraMed Technologies Ltd
Izotropic Announces AGM Results
British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025. Company mat
2025-12-31 4:31 PM EST | Izotropic Corporation
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceed
Biotechnology, Pharmaceuticals, Health
2025-12-31 2:38 PM EST | Hemostemix Inc.
Cheelcare Announces Second Quarter Fiscal 2026 Financial Results
Markham, Ontario--(Newsfile Corp. - December 30, 2025) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced its financial results for the second quarter ended October 31, 2025. All figures are in Canadian dollars unless otherwise noted. Operational Highlights (Three Months Ended October 31, 2025) Manufacturing transition completed: Successfully completed the transition of inventory, equipme
2025-12-30 4:30 PM EST | Cheelcare Inc.
Aleen Inc. - 2025: A Year of Insight, Clarity, and Growth
Toronto, Ontario--(Newsfile Corp. - December 30, 2025) - Aleen Inc. (CSE: ALEN-U), a digital wellness company, reflects on 2025 as a year marked by meaningful growth, product development, and strategic progress in the digital wellness space - all delivered within a safe, transparent, and non-medical framework. In 2025, Aleen Inc. reached an important corporate milestone with its listing on the Canadian Securities Exchange (CSE) on June 6, 2025, trading under the ticker ALEN.U. Th
2025-12-30 8:00 AM EST | Aleen Inc.
Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced a year-end recap of its pivotal 2025 achievements. The company delivered remarkable financial performance, operational expansion, and strategic milestones, positioning itself for sustained growth and an anticipated Nasdaq uplisting. "2025 has been a defining year of execution and momentum f
Healthcare and Hospitals, Health
2025-12-29 9:00 AM EST | Adia Nutrition Inc.
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-29 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare
Healthcare and Hospitals, Health
2025-12-24 8:00 AM EST | Obesity Medicine Association
A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors
Franklin, Tennessee--(Newsfile Corp. - December 23, 2025) - From global stages and scientific breakthroughs to philanthropic leadership and international recognition, 2025 has marked a defining year for Dr. Christina Rahm. As Chief Science Officer of The ROOT Brands and founder of DRC Ventures, Dr. Rahm continues to lead at the intersection of science, sustainability and purpose-driven innovation. Her work this year has expanded far beyond the laboratory, spanning continents, empowering commu
Biotechnology, Food / Beverages, Health
2025-12-23 11:41 AM EST | DRC Ventures
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physic
Biotechnology, Pharmaceuticals, Health
2025-12-23 9:10 AM EST | Hemostemix Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
LIS Technologies Inc. Announces Critical Regulatory Milestone with Receipt of a State of Tennessee Radioactive Material License for Its State-of-the-Art Test Demonstration Facility Located at the K-1330 Building on the Historic K-25 Site
Oak Ridge, Tennessee--(Newsfile Corp. - December 23, 2025) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that it has received a Radioactive Material License from the State of Tennessee for its state-of-the-art Test Demonstration Facility located in the K-1330 building on the historic K-25 site in Oak Ridge, Tennessee.
Technology, Mining and Metals, Energy, Health
2025-12-23 8:10 AM EST | LIS Technologies Inc.
Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has received aggregate gross proceeds of approximately CAD$590,000 through the exercise of previously issued common share purchase warrants and the closing of a corporate loan. The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for
Technology, Biotechnology, Health
2025-12-22 12:00 PM EST | Restart Life Sciences Corp.
Functional Brands Inc. Launches Kirkman's(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin
Lake Oswego, Oregon--(Newsfile Corp. - December 22, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced the release of its Skin, Beauty & Anti-Aging Bundle by Kirkman®; a holistic solution designed to promote healthy, youthful skin by supporting detoxification, cellular renewal, and protection against environmental stressors. This carefully crafted bundle combines four powerful ingredients—Reduced Glutathione,
Household / Consumer / Cosmetics, Health
2025-12-22 8:00 AM EST | Functional Brands Inc.
Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart" or the "Company") is pleased to announce that it has signed a binding letter of intent dated December 21st, 2025 (the "LOI"), which sets out the proposed terms by which the Company would acquire 100% of the shares of Holy Crap Foods Inc. ("Holy Crap"), from Happy Belly Food Group Inc. (CSE: HBFG) (the "Ac
Technology, Biotechnology, Health
2025-12-22 8:00 AM EST | Restart Life Sciences Corp.
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighte
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-22 7:00 AM EST | Cannabis Bioscience International Holdings
New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide
Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase Quality Improvement (QI) initiative designed to strengthen obesity care delivery across diverse outpatient clinical settings in the United States. This initiative offers OMA members a unique opportunity to enhance systems of care, streamline workflows, and implement proven, evidence-based interventions for patients with obesity. This program is a c
Healthcare and Hospitals, Health
2025-12-18 2:00 PM EST | Obesity Medicine Association